254 reports of this reaction
1.4% of all BRENTUXIMAB VEDOTIN reports
#18 most reported adverse reaction
SEPSIS is the #18 most commonly reported adverse reaction for BRENTUXIMAB VEDOTIN, manufactured by SEAGEN INC.. There are 254 FDA adverse event reports linking BRENTUXIMAB VEDOTIN to SEPSIS. This represents approximately 1.4% of all 18,008 adverse event reports for this drug.
Patients taking BRENTUXIMAB VEDOTIN who experience sepsis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEPSIS is a less commonly reported adverse event for BRENTUXIMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to sepsis, the following adverse reactions have been reported for BRENTUXIMAB VEDOTIN:
The following drugs have also been linked to sepsis in FDA adverse event reports:
SEPSIS has been reported as an adverse event in 254 FDA reports for BRENTUXIMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEPSIS accounts for approximately 1.4% of all adverse event reports for BRENTUXIMAB VEDOTIN, making it a notable side effect.
If you experience sepsis while taking BRENTUXIMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.